AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03830671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-month regimen containing 6 anti-TB drugs
Description: Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT03129893 — intervention group
Intervention type: DEVICE
Intervention: Cuffed tracheal tubes
Description: Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO and as eye drops
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given SC
Study NCT00061945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT, IV, and PO
Study NCT03665220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic adjustments
Description: The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
Study NCT03665220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy plus ergonomic adjustments
Description: This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
Study NCT03665220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare education
Description: This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: Given PO
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV and PO
Study NCT00061945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Given PO
Study NCT00061945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00061945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01031225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA 9090
Description: STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Study NCT02680730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study NCT01854515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Study NCT01854515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study NCT03220152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine / tenofovir 200/300 mg
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Study NCT04616079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490
Study NCT01776645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training Course
Study NCT03691038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg bid
Description: Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
Study NCT03691038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 25mg, 50mg
Description: Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
Study NCT04616079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490
Study NCT02958644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotics
Description: 12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
Study NCT04863326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices
Study NCT04863326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as usual
Study NCT02958644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12g / day placebo (polydextrose) supplemented orally for 90 days
Study NCT00780091 — intervention group
Intervention type: OTHER
Intervention: classical monitoring strategy
Description: intensive on-site monitoring, consistently with the pharmaceutical industry practices
Study NCT00780091 — intervention group
Intervention type: OTHER
Intervention: optimized monitoring strategy
Description: optimized on-site monitoring, depending on patient's risk
Study NCT03622125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vital signs
Description: Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
Study NCT01108172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Ward
Description: A multidisciplinary team to optimize medical and social care for patients residing in their own homes
Study NCT01108172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care provided to patients after discharge from hospital
Study NCT03035617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
Study NCT03035617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: In control arm mesh will be soaked in normal saline solution as is routinely done.
Study NCT04260581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Determination of drug effects through amantadine cessation
Description: Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
Study NCT03928613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tablet based Cognitive Training based on location information
Description: Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
Study NCT01253902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.01%
Description: One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
Study NCT01902849 — intervention group
Intervention type: OTHER
Intervention: blood sampling for IL measurement
Description: Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery
Study NCT04287933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain insertion
Description: insertion of a drain
Study NCT01467323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Injected subcutaneously (under the skin) twice daily
Study NCT01467323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Injected subcutaneously (under the skin) twice daily
Study NCT04320680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: description of a lupus patient cohort
Description: description of a lupus patient cohort
Study NCT00761839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-care summary
Description: The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals.
Study NCT00761839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patients in the control group will receive usual counseling for self-management.
Study NCT03634579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Guided Focal Laser Interstitial Thermal Ablation
Description: The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps.
Study NCT04280198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Parenting Videos
Description: Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
Study NCT04280198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Boxes
Description: There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
Study NCT05809570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient.
Study NCT02262845 — intervention group
Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts
Study NCT01789944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
Study NCT01927445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality improvement toolkit
Description: educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
Study NCT03971617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: each hydrogen tablet contains 80mg magnesium
Study NCT03971617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: matching placebo tablet
Study NCT02925975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
Study NCT02925975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
Study NCT02925975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
Study NCT01518985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia
Description: Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
Study NCT01518985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline (0.9%)
Description: Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
Study NCT01518985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Description: One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
Study NCT01518985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cigarette smoking
Description: One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
Study NCT02925975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
Study NCT02925975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
Study NCT02925975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine endoscopic procedures
Description: These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
Study NCT02925975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine endoscopic procedures
Description: These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
Study NCT03673436 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar spinal fusion
Description: The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
Study NCT02411110 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study NCT01253902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost ophthalmic solution 0.004%
Description: One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
Study NCT01253902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost ophthalmic solution 0.005%
Description: One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
Study NCT02123264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid: 5 mg/year x 2 years
Study NCT02411110 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study NCT02411110 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: LiRIS Placebo
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
Study NCT02157376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: iv esomeprazole 30 min intermittent infusions given for maximum 14 days
Study NCT02565641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
Study NCT02565641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
Study NCT01385059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Given PO
Study NCT01385059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy and pelvic lymph node dissection
Study NCT01385059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy and pelvic lymph node dissection
Study NCT02157376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
Study NCT01385059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01385059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01385059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01385059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03867331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
Study NCT03867331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
Study NCT03867331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
Study NCT03867331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum challenge
Description: Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
Study NCT01494285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARK-E021 5%
Description: Topically applied once daily at bedtime